Comparative Pharmacology
Head-to-head clinical analysis: FEMCON FE versus PHILITH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEMCON FE versus PHILITH.
FEMCON FE vs PHILITH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing norethindrone and ethinyl estradiol. Inhibits ovulation via suppression of gonadotropins (FSH, LH); increases cervical mucus viscosity, impairing sperm penetration; alters endometrial receptivity.
PHILITH is a combined oral contraceptive containing ethinyl estradiol and drospirenone. Ethinyl estradiol suppresses gonadotropin release, while drospirenone is a progestin with antiandrogenic and antimineralocorticoid activity, inhibiting ovulation and altering cervical mucus.
One tablet (norethindrone 0.5 mg + ethinyl estradiol 35 mcg) orally once daily for 28 days.
1 mg orally once daily
None Documented
None Documented
The terminal elimination half-life of ethinyl estradiol is 13-18 hours; for norethindrone, it is 7-12 hours. Both allow once-daily dosing for contraceptive efficacy.
Terminal half-life 12 hours; clinically relevant for twice-daily dosing with steady state reached after 2-3 days.
Renal excretion accounts for approximately 40-60% of the dose as metabolites; fecal excretion is about 20-30% via bile. Unchanged drug excretion is minimal.
Renal: 90% unchanged; biliary/fecal: 10% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive